Nyxoah Raises $110M for Genio U.S. Launch

Nyxoah completed a $95 million equity financing and expects a $15 million loan tranche, totaling $110 million. The capital will accelerate the U.S. commercial launch of the Genio system, a leadless hypoglossal neurostimulation therapy for obstructive sleep apnea. CEO Olivier Taelman called it a defining moment for the company.